Mark E. Bunnage, EVP, Chief Scientific Officer: Vertex Pharmaceuticals VRTX Sell · Filed 05/19

Trade details

Type: Insider sale
Amount: $14,963.85
Shares · price: 33 sh · $453.45 a share
Held after: 7,284 sh
Stock: Vertex Pharmaceuticals VRTX
Person: Mark E. BunnageEVP, Chief Scientific Officer
Trade date: 26/05/15
Filed: 26/05/19
Days to filing: 4 days

Sold 0.5% of holdings

Share of holding sold: 0.5%

Vertex Pharmaceuticals trades, last 26 weeks

What else happened in Vertex Pharmaceuticals around then

Filed or reported within 30 days of the trade day · 04/15~06/14

Mark E. Bunnage's recent trades

Mark E. BunnageEVP, Chief Scientific Officer
Planned sale10b5-1 planVertex Pharmaceuticals
Planned sale10b5-1 plan
Vertex Pharmaceuticals
VRTX
$15K
33 sh
$15K
Filed 05/15
Traded 05/15
Mark E. BunnageEVP, Chief Scientific Officer
Sell10b5-1 planVertex Pharmaceuticals
Sell10b5-1 plan
Vertex Pharmaceuticals
VRTX
$301.5K
620 sh
$301.5K
Filed 02/26
Traded 02/25
Mark E. BunnageEVP, Chief Scientific Officer
Planned sale10b5-1 planVertex Pharmaceuticals
Planned sale10b5-1 plan
Vertex Pharmaceuticals
VRTX
$301.5K
620 sh
$301.5K
Filed 02/25
Traded 02/25
Mark E. BunnageEVP, Chief Scientific Officer
Sell10b5-1 planVertex Pharmaceuticals
Sell10b5-1 plan
Vertex Pharmaceuticals
VRTX
$1.2M
2,437 sh
$1.2M
Filed 02/19
Traded 02/17
Mark E. BunnageEVP, Chief Scientific Officer
Sell10b5-1 planVertex Pharmaceuticals
Sell10b5-1 plan
Vertex Pharmaceuticals
VRTX
$559.9K
1,182 sh
$559.9K
Filed 02/19
Traded 02/18